The global market for dry eye syndrome therapeutics estimated to reach $7.5 billion by 2029, growing at a CAGR of 5.1% over the forecast period, driven by increasing prevalence of dry eye syndrome, aging population, increase in autoimmune diseases, contact lens wear and digital screen time worldwide.
- Dry eye disease or dry eye syndrome (DES) is a multifactorial, age-related chronic progressive disease of the ocular surface resulting in pain, visual impairment, tear film hyperosmolarity and instability, and inflammation.
- Dry eye disease is characterized by a reduction in tear volume, rapid breakup of the tear film, or an increase in the evaporative properties of the tear film layer.
- Dry eye disease can also limit patients’ ability to tolerate contact lenses and can impact satisfaction with post-op cataract and refractive patients.
- Dry eye disease is characterized by a reduction in tear volume, rapid breakup of the tear film, or an increase in the evaporative properties of the tear film layer.
The exact prevalence of dry eye disease is unknown due to the difficulty in defining the disease and the lack of a single diagnostic test to confirm its presence. Dry eye disease is highly prevalent and growing, affecting more than 739 million people globally.
- In the U.S., dry eye disease affects an estimated 14.6% of the adult population, or 38 million adults, resulting in greater than $55.4 billion in annual indirect costs, such as reductions in productivity. Prevalence of dry eye disease continues to grow due to an aging population, increase in autoimmune diseases, contact lens wear and digital screen time.
Dry eye disease is commonly treated with a variety of over-the-counter eye drops, often referred to as artificial tears; a nasal spray, Tyrvaya (Oyster Point Pharma) and four FDA-approved prescription eyes drop therapies asbRestasis (Allergan/Abbvie), Xiidra (Novartis), Cequa (Sun Pharma) and Eysuvis (Kala Pharmaceuticals). Other products used by patients suffering from dry eye disease include ointments, gels, warm compresses, omega-3 fatty acid supplements and a number of medical devices.
- Currently marketed prescription products often lack efficacy and also have a significant number of treatment burdens, including significant instillation site discomfort, delayed onset of efficacy up to twelve weeks, taste altering effects, resulting in relatively low persistence rates.
- The dry eye marketspace remains a very large and underserved market and that the limitations of currently approved prescription treatments for dry eye disease reflect why only 2.0 million patients are on a prescription therapy at any given time.
The global market for dry eye syndrome therapeutics research report provides market size ($million 2019 to 2029), market share analysis, growth trends and forecast (CAGR%, 2023 to 2029).
The global market for dry eye syndrome therapeutics segmented by type (evaporative dry eye syndrome, aqueous tear-deficient dry eye syndrome), by drug (Restasis, Xiidra, Cequa, Eysuvis, Tyrvaya, others), by product (cyclosporine, oral corticosteroids, artificial tears, punctal plugs, omega supplements, others), by dosage form (gels, eye solutions, capsules & tablets, eye drops, ointments), by sales channel (prescription, over-the-counter), by distribution channel (hospital pharmacies, online pharmacies, retail pharmacies), and geography.
- There is significant published research that suggests that inflammation plays a major role in the development of dry eye disease. Dry eye disease can have a significant impact on quality of life and can potentially cause long-term damage to the ocular surface.
- Due to the impact of dry eye disease on tear film dynamics, the condition can affect performance of common vision-related activities such as reading, using a computer and driving, and can lead to complications associated with visual impairment. Dry eye disease is commonly treated by ophthalmologists and optometrists.
- Based on the disease type, the evaporative dry eye syndrome segment accounted for the largest share of the total DES therapeutics market, and also expected to grow aa the fastest rate during the forecast period, owing to easy availability of products in the market, increase in screen time, reduced rate of blinking, and age-related reduced tear formation.
- In terms of the drugs used, the Restasis [cyclosporin emulsion (an oily liquid mixture)] segment accounted for the largest revenue share of the total DES market, driven by its wider application and adoption in treating chronic dry eye symptoms with less side effects.
- However, the revenue expected to fall in the coming years due the entry of generic Restasis by Mylan Pharmaceuticals in the market.
- On the other hand, the Xiidra (lifitegrast) segment anticipated to grow at a lucrative rate during the forecast period, being the first medication in a new class of lymphocyte function-associated antigen-1 (LFA-1) antagonist which has been approved for the treatment of the signs and symptoms of dry eye disease. It also addresses chronic inflammation associated with dry eye disease.
- However, the revenue expected to fall in the coming years due the entry of generic Restasis by Mylan Pharmaceuticals in the market.
- Among the products, the cyclosporine segment held the largest revenue share of the global DES market, and also anticipated to expand at the fastest rate in the coming years, owing to the long-standing use of medications, its effectiveness for dry eye disease symptoms.
- Artificial tears are intended to supplement insufficient tear production or improve tear film instability but are primarily saline-based and provide only temporary relief. Restasis and Cequa, both calcineurin inhibitor immunosuppressants, which have been approved and are indicated to increase tear production, address chronic inflammation associated with dry eye disease.
The global market for dry eye syndrome therapeutics research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.
- By geography, the North America region, followed by Europe region dominated to global dry eye disease therapeutics market, owing to presence of a large target population, early access and a high rate of treatment adoption in the developed region.
- Around 34 million people in US are estimated to have dry eyes, of which only half are diagnosed, only 1.6 million are treated by prescription (Rx) drugs. A number of therapies are currently available for the treatment of dry eye disease in the U.S.
- The most commonly used treatments for dry eye disease in the U.S. are over-the-counter eye drops, often referred to as artificial tears, and four FDA-approved prescription eye drops as Restasis, Xiidra, Cequa and Eysuvis. Although dry eye disease is one of the most common reasons patients visit eye care professionals (ECPs) in the U.S., it is estimated that only 17.3 million adults have been diagnosed with dry eye disease by an ECP, due in part to lack of education and insufficient awareness on the part of the patient.
- Around 34 million people in US are estimated to have dry eyes, of which only half are diagnosed, only 1.6 million are treated by prescription (Rx) drugs. A number of therapies are currently available for the treatment of dry eye disease in the U.S.
- On the other hand, the Asia Pacific region estimated to be the fastest-growing segment over the forecast period, due to rising prevalence of dry eye disease, improving healthcare infrastructure, and availability of low-cost treatment in the emerging countries.
In addition, the global market for dry eye syndrome therapeutics report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major competitors operating in the global market for dry eye syndrome therapeutics and profiled in this report include AFT Pharmaceuticals, AbbVie, Inc., Bausch & Lomb, Johnson & Johnson Services, Inc., Kala Pharmaceuticals, Inc., Novartis AG, OASIS Medical, Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Santen Pharmaceutical Co., Ltd., and Sun Pharmaceutical Industries Ltd.
- Type
- Evaporative Dry Eye (EDE) Syndrome
- Aqueous Tear-Deficient (ADT) Dry Eye Syndrome
- Drug
- Restasis (cyclosporin emulsion)
- Xiidra (lifitegrast)
- Cequa (cyclosporine solution)
- Eysuvis (loteprednol etabonate suspension)
- Tyrvaya (varenicline solution)
- Others
- Product
- Cyclosporine
- Oral Corticosteroids
- Artificial Tears
- Punctal Plugs
- Omega Supplements
- Others
- Dosage Form
- Gels
- Eye Solutions
- Capsules & Tablets
- Eye Drops
- Ointments
- Sales Channel
- Prescription
- Over the Counter (OTC)
- Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Geography
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LA)
- Rest of the World
- Company Profiles
- AFT Pharmaceuticals
- AbbVie, Inc.
- Bausch & Lomb
- Johnson & Johnson Services, Inc.
- Kala Pharmaceuticals, Inc.
- Novartis AG
- OASIS Medical
- Otsuka Pharmaceutical Co., Ltd.
- Oyster Point Pharma, Inc.
- Santen Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
To request Table of Contents and Sample Pages of this report:
https://www.ihealthcareanalyst.com/report/dry-eye-syndrome-treatment-market/
Related publications:
